$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb

$mtnb Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000114420415048999 Filed on August 13, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$77.00K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$1.355M	$1.118M
YoY Change	21.15%	365.72%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K
YoY Change	0.0%
% of Gross Profit
Operating Expenses	$2.479M	$2.420M
YoY Change	2.41%	604.92%
Operating Profit	-$2.402M	-$2.420M
YoY Change	-0.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$2.738K	-$5.385K
YoY Change	-49.16%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings	-$2.405M	-$2.426M
YoY Change	-0.88%	606.6%
Net Earnings / Revenue	-3122.77%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding	56.90M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.610M	$6.650M
YoY Change	-0.6%	1483.33%
Cash & Equivalents	$6.605M	$6.647M
Short-Term Investments
Other Short-Term Assets	$220.0K	$40.00K
YoY Change	450.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.880M	$6.686M
YoY Change	2.91%	1491.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$363.2K	$361.6K
YoY Change	0.43%
Goodwill	$1.385M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$220.0K	$320.0K
YoY Change	-31.25%
Total Long-Term Assets	$4.982M	$677.8K
YoY Change	635.04%
TOTAL ASSETS
Total Short-Term Assets	$6.880M	$6.686M
Total Long-Term Assets	$4.982M	$677.8K
Total Assets	$11.86M	$7.363M
YoY Change	61.1%	1653.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$745.6K	$281.1K
YoY Change	165.24%	368.48%
Accrued Expenses	$339.8K	$547.3K
YoY Change	-37.91%
Deferred Revenue
YoY Change
Short-Term Debt	$10.00K	$0.00
YoY Change		-100.0%
Long-Term Debt Due	$30.00K	$40.00K
YoY Change	-25.0%
Total Short-Term Liabilities	$1.136M	$870.0K
YoY Change	30.6%	987.5%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$30.00K
YoY Change	-100.0%	-93.48%
Other Long-Term Liabilities	$840.0K
YoY Change
Total Long-Term Liabilities	$840.0K	$30.00K
YoY Change	2700.0%	-93.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.136M	$870.0K
Total Long-Term Liabilities	$840.0K	$30.00K
Total Liabilities	$3.230M	$910.0K
YoY Change	254.95%	68.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.03M	-$8.396M
YoY Change	126.62%
Common Stock	$5.698K	$3.200K
YoY Change	78.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.629M	$6.457M
YoY Change
Total Liabilities & Shareholders Equity	$11.86M	$7.363M
YoY Change	61.1%	1653.17%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$2.405M	-$2.426M
YoY Change	-0.88%	606.6%
Depreciation, Depletion And Amortization	$10.00K	$10.00K
YoY Change	0.0%
Cash From Operating Activities	-$2.220M	-$1.850M
YoY Change	20.0%	560.71%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$70.00K
YoY Change	-42.86%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$40.00K	-$70.00K
YoY Change	-42.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.240M	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-2.220M	-1.850M
Cash From Investing Activities	-40.00K	-70.00K
Cash From Financing Activities	4.240M	0.000
Net Change In Cash	1.980M	-1.920M
YoY Change	-203.12%	860.0%
FREE CASH FLOW
Cash From Operating Activities	-$2.220M	-$1.850M
Capital Expenditures	-$40.00K	-$70.00K
Free Cash Flow	-$2.180M	-$1.780M
YoY Change	22.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	216317	USD
CY2015Q2	us-gaap	Other Long Term Investments OtherLongTermInvestments	216475	USD
CY2015Q2	us-gaap	Assets Assets	11862074	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	339995	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2590713	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6605498	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	114425	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	114996	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2805138	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	6880351	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	363197	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	271155	USD
CY2014Q4	us-gaap	Assets Assets	3361450	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	2478794	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2404532	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	27649577	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14051764	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19026407	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2227896	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	8628868	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3361450	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11862074	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	745551	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	802746	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	339835	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	44362	USD
CY2015Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	33580	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1118263	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	100000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-19827	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-5213	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4192949	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10840428	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1136205	USD
CY2014Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	15291	USD
CY2015Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	0	USD
CY2014Q4	mtnb	Contract Research Receivables ContractResearchReceivables	0	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1354728	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1302236	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1124066	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	2420487	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1118251	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2425872	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	3230	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	5698	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16276430	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2420487	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32000000	shares
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014Q4	us-gaap	Liabilities Liabilities	1133554	USD
CY2015Q2	us-gaap	Goodwill Goodwill	1384674	USD
CY2014Q4	us-gaap	Goodwill Goodwill	0	USD
CY2015Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3017377	USD
CY2014Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	USD
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	10000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	7239	USD
CY2015Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	843674	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	1253327	USD
CY2015Q2	mtnb	Contract Research Receivables ContractResearchReceivables	59857	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55942013	shares
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2401794	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2738	USD
CY2015Q2	mtnb	Contract Research Revenue ContractResearchRevenue	77000	USD
CY2014Q2	mtnb	Contract Research Revenue ContractResearchRevenue	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2192031	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2803141	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2357483	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2301907	USD
	us-gaap	Operating Expenses OperatingExpenses	4549514	USD
	us-gaap	Operating Expenses OperatingExpenses	5105048	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4564895	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4974643	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32000000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45815657	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4549514	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4970412	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15381	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4231	USD
	mtnb	Contract Research Revenue ContractResearchRevenue	134636	USD
	mtnb	Contract Research Revenue ContractResearchRevenue	0	USD
	us-gaap	Depreciation Depreciation	19931	USD
	us-gaap	Depreciation Depreciation	20583	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	547589	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	733761	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4471	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	158	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-115678	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	173983	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3935177	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4539399	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	257772	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38734	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-257772	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	32020	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5385	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8522164	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4014785	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6647479	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1477836	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	162520	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-483925	USD
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	111095	USD
	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	0	USD
	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	14213	USD
	us-gaap	Increase Decrease In Contract Receivables Net IncreaseDecreaseInContractReceivablesNet	0	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	70754	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	2119689	USD
	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	0	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	10200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46005361	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18309082	shares
	mtnb	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	8500000	USD
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	39250000	shares
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	401000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5353417	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1630000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	113195	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6755361	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.05
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.93
CY2013Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9541706	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04	pure
CY2014Q2	mtnb	Sharebased Compensation Arrangement By Sharebased Payment Award Increase Of Shares Offering Date SharebasedCompensationArrangementBySharebasedPaymentAwardIncreaseOfSharesOfferingDate	January 1, 2015
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	90854	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	157321	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	160257	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	163193	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	406147	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	977772	USD
CY2013Q4	us-gaap	Lessor Leasing Arrangements Operating Leases Term Of Contract LessorLeasingArrangementsOperatingLeasesTermOfContract	P7Y
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12723	USD
CY2014Q2	mtnb	Increase Decrease In Lease Rental Expense IncreaseDecreaseInLeaseRentalExpense	14200	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2175	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	300000	USD
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56967690	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56967690	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32292650	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32292650	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">[2]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Use of Estimates</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.3pt; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">[4]</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt" align="justify"><font style="FONT-SIZE: 10pt">Concentration of Credit Risk</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. Cash balances are maintained principally at one major U.S. financial institution and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. At various times throughout the period ended June 30, 2015, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	mtnb	Effectiveness Of Registration Statement Description EffectivenessOfRegistrationStatementDescription	The Registration Statement was filed on June 9, 2015 and declared effective on July 23, 2015. The Company is required to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the Securities Act), for a period of one year from the date it is declared effective by the SEC or for such shorter period ending on the earlier of the date when all the registerable securities covered by the registration statement have been sold or such time as all of the registerable securities covered by the registration statement can be sold under Rule 144 without any volume limitations (the Effectiveness Period). If the Company does not maintain the effectiveness of the registration statement during the Effectiveness Period, subject to certain limitations and the right of the Company to suspend the use of the prospectus for certain periods, the Company shall pay to each holder of registrable securities purchased in 2015 Private Placement an amount in cash equal to half of one percent (0.5%) of such holders investment amount, subject to a maximum penalty equal to six percent (6%) of such holders investment amount, on every thirty (30) day anniversary of such failure to maintain the registration statement until such failure was cured; provided however that such liquidated damages shall be paid only with respect to registrable securities that cannot then be immediately resold in reliance on Rule144.
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	734000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	548000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	114861	shares
	mtnb	Security Deposits Reduced By Straight Line Basis Description SecurityDepositsReducedByStraightLineBasisDescription	Starting June1, 2015, this deposit can be reduced by $100,000 on an annual basis, down to $50,000, as long as the Company makes timely rental payments
CY2015Q1	mtnb	Percentage Of Approval Shareholders PercentageOfApprovalShareholders	1	pure
CY2015Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	2873035	USD

Files In Submission

Name	View Source	Status
0001144204-15-048999-index-headers.html	Edgar Link	pending
0001144204-15-048999-index.html	Edgar Link	pending
0001144204-15-048999.txt	Edgar Link	pending
0001144204-15-048999-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mtnb-20150630.xml	Edgar Link	completed
mtnb-20150630.xsd	Edgar Link	pending
mtnb-20150630_cal.xml	Edgar Link	unprocessable
mtnb-20150630_def.xml	Edgar Link	unprocessable
mtnb-20150630_lab.xml	Edgar Link	unprocessable
mtnb-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v417136_10q.htm	Edgar Link	pending
v417136_ex31-1.htm	Edgar Link	pending
v417136_ex31-2.htm	Edgar Link	pending
v417136_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb

2015 Q2 Form 10-Q Financial Statement

#000114420415048999 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB Matinas BioPharma Holdings Inc Stock $mtnb

2015 Q2 Form 10-Q Financial Statement

#000114420415048999 Filed on August 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTNB
Matinas BioPharma Holdings Inc Stock $mtnb